Overview

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of veliparib that can be given while a patient is receiving radiation therapy.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center
Treatments:
Veliparib